Title: Genetic manipulation of human T cells for cancer immunotherapy
Dr. Avery Posey is an Assistant Professor at the University of Pennsylvania Perelman School of Medicine. He received Ph.D. from the University of Chicago (2011) and his postdoctoral training at the University of Pennsylvania. He is a classically trained molecular and developmental geneticist and an expert in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. His current research is focused on the redirection of T cells to target cancer-specific epitopes, especially glycan haptens and O-glycopeptide epitopes formed through altered glycosylation in cancer cells, investigation of optimal CAR-T signaling for effective anti-tumor responses and durable persistence in solid tumors, and CRISPR/Cas9-mediated gene-editing strategies for improved engineered T cells (knockout of checkpoint molecules - PD-1, CTLA-4, etc.; HDR knock-in of combination therapies). The major objective of his research is to increase the efficacy of engineered T cells in solid tumors.
Title: Cancer immunotherapy by manipulation of tumor-associated glycans
Dr. Heinz Läubli received his M.D. and Ph.D. at the Institute of Physiology, University of Zürich (Switzerland). He is now an Assistant Professor and a Research group leader at the University of Basel and an Attending physician in the Division of Oncology, and Head of Glycobiology Research in the Department of Biomedicine, at the University Hospital Basel. Dr. Heinz’s research interests are to improve immunotherapy for cancer patients by using translational in vitro and in vivo tumor models, performing correlative analysis of patients treated with immunotherapy, and conducting early clinical interventional trials. His group has been studying the interaction between siaologlycans and their interaction with Siglec receptors on immune cells. It has demonstrated that this pathway can be targeted to augment T-cell stimulation and tumor control. His research goals also include the improvement of cancer immunotherapy by modifying glycans in the tumor microenvironment and glycans of cellular products for adoptive cell therapies, including genetically modified T cells.
The Institue of Biology and Experimental Medicine, Argentina
Dr. Mariño received her Ph.D. in Chemistry from the University of Buenos Aires. She continued her training as a postdoc at the University of Dundee (Scotland, UK) and later, at the National Institute for Bioprocessing, Research, and Training (Dublin, Ireland), integrating her chemical vision of carbohydrates into the biochemistry of glycans and the structural analysis of glycoconjugates in physiological and pathological contexts. After relocating to Argentina, she established the Functional and Molecular Glycomics Lab (Institute of Biology and Experimental Medicine). As an Independent Researcher at CONICET, she focuses on how inflammatory conditions could alter the glycome in inflammatory bowel diseases and colorectal cancer and whether these changes can promote the establishment of altered lectin-glycan interactions and, in doing so, influence the immune response. Her goal is to capitalize on glycoimmunological mechanisms that could potentially re-wire immune circuits in these pathologies, providing novel opportunities for translational medicine.
Based on her glycoanalytical experience, she also offers consultancies on glycosylation analysis to the Latin American Life Sciences Industry. She received several prizes for her work, including the "Carlos B. Udaondo" award from the National Academy of Medicine (2019). She is the current National Representative for Argentina at the International Glycoconjugate Organization.
Dr. Guerardel is a senior researcher for CNRS (Lille University, France) and an Invited Professor at iGCORE (Gifu University, Japan). His research focuses on the structure-to-function relationships of complex carbohydrates, from microorganisms to higher eukaryotes, mostly in the context of host-pathogen interaction. His main objective is to understand how the glycans from both host and pathogen fine-tune the infectious process and how they may be used as diagnosis or therapeutic tools, with a keen interest in mycobacterial, fungus, and viral infections. To reach this goal, Dr. Guerardel integrates a wide range of scientific approaches, including synthetic chemistry, structural analysis using NMR spectroscopy and mass spectrometry, structural biology of proteins, and enzymology.
Title: Cell-based Mucin Array for Discovery and Characterization of Mucinase/O-glycanase and Carbohydrate Binding Module
Dr. Narimatsu is an Associate Professor at Copenhagen Center for Glycomics, Ph.D. (2008, Tsukuba University, Japan). His study focuses on the structure, biosynthesis, and genetic regulation of complex carbohydrates. He received training for eight years at the glycobiology lab, Research Center for Medical Glycoscience (RCMG) in Japan. Joined a Center of Excellence in Glycomics funded by the Danish National Research Foundation at the University of Copenhagen in 2012 and contributed to developing a comprehensive and high-throughput platform for CRISPR/Cas9 gene targeting of the human glycome (GlycoCRISPR), a large library of glycoengineered cells (GlycoDisplay), a cell-based platform for the display and production of human Mucin tandem repeat (MucinDisplay). His research interests include a basic understanding of genetic regulation and biosynthesis of protein glycosylation, consequences of deficiencies in glycosylation in diseases, and biomedical applications.
His group has taken a global "glycogenome" engineering approach to protein glycosylation and proposed a Cell-Based glycan array platform to display the human glycome–i.e., display of all human glycans on proteins, proteoglycans, and lipids. This self-renewable array is useful for discovering biological interactions involving glycans, and screening of true high-affinity interactions with glycans requires the natural biological context of specific proteins and cell surfaces.
University of New Mexico School of Medicine, United States
Title: Galectins in lysosomal and autophagic homeostasis
Dr. Vojo Deretic is the department chair of the Department of Molecular Genetics and Microbiology at the University of New Mexico School of Medicine and the director of the NIH-funded Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical Research Excellence. The AIM center aims to promote autophagy research nationally and internationally and to develop a cadre of junior faculty along with senior experts in this area to study fundamental mechanisms and how autophagy intersects with a broad spectrum of human disease and health states. He received his undergraduate, graduate, and postdoctoral education in Belgrade, Paris, and Chicago. Dr. Deretic’s main contributions to science come from studies by his team on the role of autophagy in infection, immunity, and inflammation. Recently, Dr. Deretic’s group developed the concept of a cellular system termed MERIT for coordinated membrane repair, removal, and replacement. This involves recognition of exposed glycoconjugates on damaged membranes, membrane repair, removal of membranes by autophagy, and replacement of membranous organelles through respective biogenesis programs.
Title: Genome-wide Analysis of Glycosaminoglycan Assembly
Dr. Ryan Weiss began his diverse scientific training by earning his B.S. in Chemistry in 2008 at Point Loma Nazarene University in San Diego, CA, USA. He then received his Ph.D. in Chemistry in 2015 at the University of California, San Diego, under the supervision of Prof. Yitzhak Tor, where he studied the design, synthesis, and application of small molecule antagonists of heparin- and heparan sulfate-protein interactions. As an NIH K12 postdoctoral fellow in Prof. Jeffrey Esko’s group at the Department of Cellular and Molecular Medicine at the University of California, San Diego, his research focused on utilizing whole-genome screening methods to investigate the regulation of heparan sulfate biosynthesis. Dr. Weiss began his independent career as an assistant professor at the Complex Carbohydrate Research Center at the University of Georgia in January 2021. Research in the Weiss Laboratory focuses on studying the structure, function, and regulation of complex carbohydrates in human biology and disease. In addition, his lab is dedicated to developing pharmacological and cell-based tools to aid in the discovery of novel targets and approaches for modulating glycan assembly in relevant human disorders.
Title: Synthetic glycan-based vaccines to combat bacterial diseases: from concept to first-in-human data and beyond
Dr. Mulard graduated as an engineer from the ESPCI (Paris, France). She received a Ph.D. in Chemistry from the University Paris 6 (UPMC, Paris, France) and was trained in glycochemistry and glycan recognition as a postdoctoral fellow at the NIH (Bethesda, MD, USA). She joined the Organic Chemistry Unit at Institut Pasteur (Paris, France), where she set up a group on the Chemistry of Bacterial Carbohydrates. Her current research interests are in the area of peptide chemistry and carbohydrate chemistry. Her research programs deal with the development of chemical tools and bioactive compounds aimed at interfering with molecular phenomena governing infectious diseases. Interfacing Chemistry, Structural Biology, Immunochemistry, and Vaccinology, the special focus has been on investigating a chemistry-driven multidisciplinary strategy toward developing original conjugate vaccines against diarrheal diseases. Dr. Mulard’s major implication in translational sciences and technology transfer has led to the first-in-human Shigella synthetic carbohydrate-based vaccine candidate. Besides actively pursuing promising routes toward the next-generation glycoconjugate vaccines, she is interested in the development of novel therapeutic agents inspired by peptide and carbohydrate scaffolds. Her contribution was distinguished on various occasions, including the 2016 Thérèse Lebrasseur award from the Fondation de France.
Title: An interface is worth a thousand pictures: An integrated systems approach to glycobiology
Dr. Daniel Bojar is a tenure-track assistant professor at the Wallenberg Centre for Molecular and Translational Medicine & the Department of Chemistry and Molecular Biology at the University of Gothenburg in Sweden, focusing on machine learning and data science in the field of glycobiology. He obtained his Ph.D. in mammalian synthetic biology at ETH Zurich and continued his postdoctoral training in computational biology at MIT & Harvard University. His group develops and applies methods to discover sequence-to-function associations and biological roles of glycans via a broad set of approaches from machine learning, data science, and bioinformatics. Daniel was awarded a Branco Weiss Fellowship - Society in Science, as well as a Foresight Fellowship, and was recognized as a "Rising Star" by the journal Advanced Science. He was also featured on the 2022 Forbes 30 Under 30 Europe list for work in Science & Healthcare.
Professor Yasuhiko Kizuka has been a researcher at Disease Glycomics Team, RIKEN, led by Dr. Naoyuki Taniguchi (2009-2017). He has joined Gifu University (Japan) as an Associate Professor since 2017, and is currently the Director and Professor of Integrated Glyco-Molecular Science Center, Institute for Glyco-core Research (iGCORE) at Gifu University.
Professor Kizuka’s glyco-related contributions include discovery of novel mode of catalytic action of glycosyltransferases, elucidation of glycosyltransferase structures and development of glycosyltransferase inhibitors. His Research Interests are (1) Regulation of glycosyltransferase activity; (2) Substrate protein selectivity of glycosyltransferases; (3) Physiological functions of N-glycan branches.
@TAIPEI, AUG 27~SEP 1 2023
To learn more about each individual speaker, please click on the photos below.
Professor Henrik Clausen is the Director of the Copenhagen Center for Glycomics. He has been working in the glycoscience field for 30 more years focusing on the structure, biosynthesis, and genetic regulation of complex carbohydrates. He studied with Professor Sen-Itiroh Hakomori in Seattle (1983-90) on blood group-related carbohydrates, glycosyltransferases, and genes.
He is a member of scientific advisory boards and consultant for Neose Technologies, ZymeQuest Inc, GlycoZym Inc, and GlycoDisplay Aps. Professor Clausen is a national representative for the International Glycoconjugate Organization (IGO) and a member of the Royal Danish Academy of Sciences and Letters.
His research focus is primarily on protein glycosylation with early contributions to isolation, cloning, and expression of many of the human glycosyltransferases involved in the biosynthesis of human glycans and especially mucin-type glycans. His group developed strategies to isolate and characterize O-glycoproteomes by use of nuclease-mediated gene engineering - the SimpleCell approach. He applies genetic engineering of the glycosylation capacities in mammalian cells for de/reconstruction of glycosylation, dissection of biological functions of glycans, and custom-design of recombinant glycoprotein therapeutics. He also applies this strategy to develop cell-based glycan arrays and, most recently, the first display of human mucin O-glycodomains.
Dr. Drickamer began working in the field of glycan-binding receptors as a postdoctoral fellow at Duke University. These receptors have been the focus of his subsequent research at Cold Spring Harbor Laboratory, the University of Chicago, Columbia University, Oxford University, and currently at Imperial College London. His work on identifying a common carbohydrate recognition led to the definition of C-type lectins as one of the major groups of glycan-binding receptors. His ongoing research is a joint project with Dr. Maureen Taylor. The aim is to develop a broad understanding of the biological roles of sugar recognition. They have used a combination of biochemical, biophysical, and molecular biological approaches to understand how carbohydrate-recognition domains provide selective recognition of glycoproteins and cell surfaces. In addition, they seek to determine how such recognition leads to the targeting of biological functions, such as innate immunity to pathogens, clearance of serum glycoproteins, cell adhesion, and cell signaling, and how genetic variation in sugar-binding receptors causes changes in their molecular properties and hence contributes to human disease. Dr. Taylor and Dr. Drickamer co-authored the textbook Introduction to Glycobiology, designed to introduce the field to students and researchers from other disciplines.
Anne Dell is Professor of Carbohydrate Biochemistry at Imperial College London. She joined Imperial College as a postdoc in 1975 after completing a PhD on peptide sequencing by mass spectrometry at the University of Cambridge. During the 1970’s and 1980’s, Anne was amongst the first investigators to apply soft ionisation mass spectrometry to carbohydrate containing biopolymers. Subsequently, she spearheaded the development of combined microchemical and mass spectrometric procedures for the identification of novel carbohydrate structures of biological and medical importance. Notably she introduced and optimised rapid techniques for characterising glycomes in a wide range of biological materials, including purified glycoproteins, body fluids, secretions, cells, tissues and organs. She has applied these procedures in worldwide collaborative research on bacterial, plant and mammalian polysaccharides, glycolipids and glycoproteins, thereby making a substantial contribution to current understanding of the functions of glycans. In particular, she has made important contributions to the structural glycobiology of mammalian sperm-egg recognition, glycan-lectin regulation of immune function, pathogen-host interactions and human reproductive glycobiology. A major focus of her current research, supported by the March of Dimes European Preterm Birth Research Centre at Imperial College, is aimed at understanding the roles that glycans play in preterm pregnancies.
Dr. Haltiwanger did his doctoral work under the direction of Dr. Robert Hill at Duke University, where he purified and characterized mammalian lectins (Fucose lectin, Mannose receptor). He moved to Dr. Gerald Hart’s lab at Johns Hopkins, where he purified and characterized O-GlcNAc transferase. He moved to Stony Brook University for his first independent appointment, where he rose through the ranks, ultimately as Chair of the Department of Biochemistry and Cell Biology. In 2015 he moved to the Complex Carbohydrate Research Center at the University of Georgia, where he is currently the Georgia Research Alliance Eminent Scholar in Biomedical Glycobiology. He has served as President of the Society for Glycobiology, Chair of the Glycobiology Gordon Conference, Editor of Glycobiology, and currently serves as Associate Editor for the Journal of Biological Chemistry. His laboratory works on unusual O-linked modifications found on two cysteine-rich modules: Epidermal Growth Factor-like (EGF) repeats and Thrombospondin Type 1 Repeats (TSRs). They have identified the enzymes that add O-fucose to EGF repeats (POFUT1) and to TSRs (POFUT2), as well as those that add O-glucose to EGF repeats (POGLUT1, 2, and 3). These enzymes are required for normal development in mice and humans. They have also worked on enzymes that elongate O-fucose on EGF repeats (Fringes) and TSRs (B3GLCT), all of which play important roles in biology. His laboratory continues to identify proteins modified by these enzymes and the effects of the modifications on their functions.
Dr. Daniel Kolarich is a research leader at the Institute for Glycomics, Griffith University, Queensland, Australia. His group is using Mass Spectrometry based techniques to understand the role of cell surface glycoconjugates, such as glycoproteins and glycolipids, in cell communication, cell signalling, host-pathogen interactions, and diseases such as cancer. Specific research interests include analytical tool development for glycomics and glycoproteomics, Vertebrata phyloglycomics, erythropoiesis, blood products, and stem cell biology, as well as applying glycomics and glycoproteomics to understand better the role of glycoconjugates in cancer and infectious diseases.
Originally from Vienna, Austria, he had the chance to learn from great mentors and scientists, from Vienna, where he received his education and Ph.D. via Sydney at Macquarie University and Berlin at the Max-Planck-Institute of Colloids and Interfaces before he finally landed at the Gold Coast to join the Institute for Glycomics. He has published over 140 peer-reviewed articles, is the vice president of the Australian Glycoscience Society, and is dedicated to promoting and integrating glycosciences.
The primary focus of Dr. Matthew Macauley’s laboratory is the immunomodulatory sialic acid-binding Siglec family of receptors. His group develops innovative approaches to probe Siglec-glycan interactions on cells and tissues and use new insights about the biological ligands of Siglecs to test hypotheses about the roles of Siglecs in controlling immune cell function.
Dr. Maureen Taylor started working on sugar-binding receptors, such as the mannose receptor of liver endothelial cells and macrophages, as a graduate student at the Royal Free Hospital in London. His subsequent research at Columbia University, Oxford University, and Imperial College London has continued to focus on related members of the C-type lectin family of glycan-binding receptors. Dr. Taylor' s ongoing research is joint with Kurt Drickamer. They use techniques of biochemistry, structural biology, molecular biology, and cell biology to gain an understanding of the molecular mechanisms underlying the recognition of glycoproteins and cell surfaces by glycan-binding proteins and the biological functions mediated by carbohydrate recognition. Of particular interest are sugar-binding receptors on cells of the immune system, for example, DC-SIGN, langerin, and dectin-2, that recognize sugars found on pathogens and have roles in innate immunity, as well as receptors involved in glycoprotein homeostasis. They have also tried to make the field of glycobiology accessible to undergraduates and researchers from other disciplines by co-authoring the textbook Introduction to Glycobiology which has now been translated into three languages.
Professor Manfred Wuhrer studied Biochemistry at Regensburg University and obtained his Ph.D. in 1999 at Giessen University, Germany. Subsequently, he joined the Leiden University Medical Center, where he was appointed assistant professor in 2005 and associate professor in 2008. In 2013, he was appointed full professor of Analytics for Biomolecular Interactions at VU University Amsterdam. In 2015 he continued his career as Head of the Center for Proteomics and Metabolomics at LUMC, Leiden. He focuses on the development of mass spectrometric methods for glycomics and glycoproteomics and their application in clinical research and biotechnology. Clinical applications cover the fields of rheumatoid arthritis, inflammatory bowel disease, colorectal cancer, prostate cancer, longevity, as well as various infectious diseases.